- Several CAF subsets with opposing clinical outcomes are identified: PI16+/SLIT2+/ADAM28+ subset enriched in responders and a tumor-promoting subset BMP4+/FAP+/MMP1+ enriched in non-responders- FAP+ CAFs enhanced tumor EMT through MIR4435-2HG associating with worse neoadjuvant chemotherapy outcomes- PI16+/SLIT2+ CAFs are identified in the responsive patient group and demonstrate immune-promoting properties such as immune cell recruitment and activation. This evidence concerns the gene ADAM28 and neoplasm.